Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07646236
Gamification Versus E-Learning for Electrocardiogram EducationTaiwan Municipal An-Nan Hospital-China Medical UniversityCompletedNot Applicable
NCT07646236Completed
Not Applicable
Gamification Versus E-Learning for Electrocardiogram EducationTaiwan Municipal An-Nan H...
NCT07645742
Pilot Study of Intermittent Fasting With Immune Checkpoint InhibitorsWest Virginia UniversityNot Yet RecruitingNot Applicable
NCT07645742Not Yet Recruiting
Not Applicable
Pilot Study of Intermittent Fasting With Immune Checkpoint InhibitorsWest Virginia University
NCT07646197
Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver DiseaseHenry Ford Health SystemRecruitingNot Applicable
NCT07646197Recruiting
Not Applicable
Effects of Peanut Consumption on Adults With Metabolic Associated Fatty Liver Di...Henry Ford Health System
NCT07644130
Bergen Four-Day Treatment (B4DT) for Obsessive-Compulsive DisorderTampere UniversityNot Yet RecruitingNot Applicable
NCT07644130Not Yet Recruiting
Not Applicable
Bergen Four-Day Treatment (B4DT) for Obsessive-Compulsive DisorderTampere University
NCT07646548
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsRegeneron PharmaceuticalsNot Yet RecruitingPhase 1
NCT07646548Not Yet Recruiting
Phase 1
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Be...Regeneron Pharmaceuticals
NCT07643831
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2- Early or Locally Advanced/Metastatic Breast CancerGenentech, Inc.Unknown
NCT07643831Unknown
—
Expanded Access Program to Provide Giredestrant to Participants With ER+, HER2-...Genentech, Inc.
NCT07646171
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+) Metastatic Breast Cancer (MBC)Tel-Aviv Sourasky Medical CenterRecruiting
NCT07646171Recruiting
—
EVERST- Everolimus After Alpelisib in Women With Hormone Receptor-positive (HR+)...Tel-Aviv Sourasky Medical...
NCT07644377
Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboembolic Pulmonary Hypertension Successfully Treated With Balloon Pulmonary AngioplastyAssistance Publique - Hôpitaux de ParisNot Yet RecruitingPhase 3
NCT07644377Not Yet Recruiting
Phase 3
Discontinuation Versus Continuation of Riociguat Monotherapy in Chronic Thromboe...Assistance Publique - Hôp...
NCT07645274
Improving Mental Healthcare Outcomes for Minoritized Veterans Through a Peer-led, Patient Navigation Program (PARTNER-MH 2.0)Indiana UniversityNot Yet RecruitingNot Applicable
NCT07645274Not Yet Recruiting
Not Applicable
Improving Mental Healthcare Outcomes for Minoritized Veterans Through a Peer-led...Indiana University
NCT07645664
Scar Management Through Serial CastingCentre hospitalier de l'Université de Montréal (CHUM)Not Yet RecruitingNot Applicable
NCT07645664Not Yet Recruiting
Not Applicable
Scar Management Through Serial CastingCentre hospitalier de l'U...
NCT07645950
Effect of the MIROKI Companion Robot on Anxiety in Pediatric RadiotherapyInstitut du Cancer de Montpellier - Val d'AurelleNot Yet Recruiting
NCT07645950Not Yet Recruiting
—
Effect of the MIROKI Companion Robot on Anxiety in Pediatric RadiotherapyInstitut du Cancer de Mon...
NCT07644481
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melphalan) Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Adult Patients With Acute Myeloid Leukemia in First Complete RemissionInstitute of Hematology & Blood Diseases Hospital, ChinaNot Yet RecruitingNot Applicable
NCT07644481Not Yet Recruiting
Not Applicable
Efficacy and Safety of the CloB2M (Clofarabine Combined With Busulfan and Melpha...Institute of Hematology &...
NCT07643779
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflux DiseaseKarabuk UniversityNot Yet Recruiting
NCT07643779Not Yet Recruiting
—
Symptom Severity, Posture, Pain, and Physical Activity in Gastroesophageal Reflu...Karabuk University
NCT07644338
The Efficacy and Safety of Temporal Interference Stimulation in the Treatment of Post-Traumatic Stress DisorderShanghai Mental Health CenterRecruitingNot Applicable
NCT07644338Recruiting
Not Applicable
The Efficacy and Safety of Temporal Interference Stimulation in the Treatment of...Shanghai Mental Health Ce...
NCT07645053
Effects of Platelet-Rich Fibrin on Postoperative Outcomes Following Nasosinusal SurgeryHospital Edmundo VasconcelosCompletedPhase 1
NCT07645053Completed
Phase 1
Effects of Platelet-Rich Fibrin on Postoperative Outcomes Following Nasosinusal...Hospital Edmundo Vasconce...
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07646405
Combined Effects of NMES and LIRT on Muscle Strength, Girth, and Physical Endurance in the Geriatric PopulationRiphah International UniversityRecruitingNot Applicable
NCT07646405Recruiting
Not Applicable
Combined Effects of NMES and LIRT on Muscle Strength, Girth, and Physical Endura...Riphah International Univ...
NCT07644013
Prospective Multicenter Registry Study of Multiple System Atrophy in ChinaPeking University First HospitalRecruiting
NCT07644013Recruiting
—
Prospective Multicenter Registry Study of Multiple System Atrophy in ChinaPeking University First H...
NCT07645443
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early PsychosisCentral Institute of Mental Health, MannheimRecruitingNot Applicable
NCT07645443Recruiting
Not Applicable
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adu...Central Institute of Ment...
Result Breakdown
Not yet recruiting10 (50%)
Recruiting7 (35%)
Completed2 (10%)
Unknown1 (5%)
not_applicable10 (50%)
Not Specified6 (30%)
Phase 12 (10%)
Phase 31 (5%)
Phase 21 (5%)